WorldHeart to begin rotary VAD trial
This article was originally published in The Gray Sheet
Executive Summary
WorldHeart announced Feb. 15 that it has received approval from the Greek Ministry of Health to begin clinical trials of its second-generation rotary ventricular assist device. WorldHeart acquired the continuous flow pump technology in February 2005 with the purchase of Medquest. The firm says that the VAD initially will be indicated as a bridge to transplant but will eventually be expanded for use as a destination therapy. Thoratec's HeartMate is the only device with FDA approval for permanent support of heart failure patients who are ineligible for transplant...